The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial
Open accessAbstract
Purpose: To determine the quality of life (QoL) of women participating in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial during the first 2 years of treatment. Patients and Methods: A total of 1,021 women were enrolled onto the QoL subprotocol. All had completed primary treatment (surgery ± radiotherapy ± chemotherapy) and were to receive 5 years of adjuvant treatment with anastrozole (n = 335), tamoxifen (n = 347), or a combination (n = 339) of both. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT–B) plus endocrine subscale (ES) at baseline and 3, 6, 12, 18, and 24 months, or until disease recurrence. The primary end point was the FACT–B Trial Outcome Index (TOI). The secondary end point was the ES total score. Analyses of individual endocrine symptoms were also explored. Results: Questionnaire completion approximated 85% of assessments available for analysis. Overall QoL for all groups improved from baseline during the 2-year period. There were no significant differences in TOI or ES scores across treatment groups. Endocrine symptoms increased between baseline and 3 months for all groups and stabilized thereafter. There were some small differences in side effect profiles. Compared with patients receiving tamoxifen only, patients receiving anastrozole only reported significantly fewer cold sweats and vaginal discharge, yet more vaginal dryness, painful intercourse, and loss of sexual interest. Conclusion: Two years of treatment with anastrozole, tamoxifen, or the combination had a similar overall QoL impact, showing gradual improvement over time. Endocrine-related symptoms for all three arms worsened initially and recovered partially during 2 years. The different symptoms experienced may assist in decision making about treatment and supportive care needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citationBrady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Cella, D., Hahn, E. A., & Dineen, K. (2002) · Quality of Life Research · doi:10.1023/a:1015276414526 · Cited by 523
Self-citationBonomi, A. E., Cella, D. F., Hahn, E. A., Bjordal, K., Sperner-Unterweger, B., Gangeri, L., Bergman, B., Willems-Groot, J., Hanquet, P., & Zittoun, R. (1996) · Quality of Life Research · doi:10.1007/bf00433915 · Cited by 400
Self-citationCELLA, D., ETON, D., FAIRCLOUGH, D., BONOMI, P., HEYES, A., SILBERMAN, C., WOLF, M., & JOHNSON, D. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00477-2 · Cited by 380
Self-citationFallowfield, L. J., Leaity, S. K., Howell, A., Benson, S., & Cella, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006263818115 · Cited by 354
Self-citationCella, D., Hernandez, L., Bonomi, A. E., Corona, M., Vaquero, M., Shiomoto, G., & Baez, L. (1998) · Medical Care · doi:10.1097/00005650-199809000-00012 · Cited by 238
Self-citation
Cited by
Mansel, R. E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R. G., Dixon, J. M., Yiangou, C., Horgan, K., Bundred, N., Monypenny, I., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj158 · Cited by 1,679
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Montazeri, A. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-32 · Cited by 770
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Major depression after breast cancer: a review of epidemiology and treatment
Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Gralow, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.10.008 · Cited by 586
(2013) · Menopause · doi:10.1097/gme.0b013e3182a122c2 · Cited by 560
Fleissig, A., Fallowfield, L. J., Langridge, C. I., Johnson, L., Newcombe, R. G., Dixon, J. M., Kissin, M., & Mansel, R. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9025-7 · Cited by 494
Self-citationSymptom Burden: Multiple Symptoms and Their Impact as Patient-Reported Outcomes
Cleeland, C. S. (2007) · JNCI Monographs · doi:10.1093/jncimonographs/lgm005 · Cited by 455
Moadel, A. B., Shah, C., Wylie-Rosett, J., Harris, M. S., Patel, S. R., Hall, C. B., & Sparano, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6027 · Cited by 398
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Rummans, T. A., Clark, M. M., Sloan, J. A., Frost, M. H., Bostwick, J. M., Atherton, P. J., Johnson, M. E., Gamble, G., Richardson, J., Brown, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.209 · Cited by 353
Sadovsky, R., Basson, R., Krychman, M., Morales, A. M., Schover, L., Wang, R., & Incrocci, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01620.x · Cited by 310
Cella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9548-1 · Cited by 286
“reunia (painful intercourse) and loss of libido, which were reported with a significantly higher incidence in patients treated with anastrozole compared with tamoxifen in the ATAC trial [20, 22].”
BackgroundSelf-citationMechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj127 · Cited by 277
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Rae, J. M., Drury, S., Hayes, D. F., Stearns, V., Thibert, J. N., Haynes, B. P., Salter, J., Sestak, I., Cuzick, J., & Dowsett, M. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs126 · Cited by 259
Self-citationCella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A., & On behalf of the ATAC Trialistsȁ9 Group (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9260-6 · Cited by 252
Self-citationMelisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155
Shelby, R. A., Edmond, S. N., Wren, A. A., Keefe, F. J., Peppercorn, J. M., Marcom, P. K., Blackwell, K. L., & Kimmick, G. G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2269-1 · Cited by 76
Zhou, C., Wu, Y., An, S., & Li, X. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131802 · Cited by 48
Mindfulness-based stress reduction in breast cancer: A qualitative analysis
Hoffman, C. J., Ersser, S. J., & Hopkinson, J. B. (2012) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2012.06.008 · Cited by 43
(2008) · PubMed · Cited by 39
Nakatani, Y., Iwamitsu, Y., Kuranami, M., Okazaki, S., Shikanai, H., Yamamoto, K., Watanabe, M., & Miyaoka, H. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu089 · Cited by 26
“Their side effects were debilitating: chemotherapy can lead to nausea, constipation, deformed nails and hair loss (6,7); radiotherapy may cause skin changes and itchiness (8,9); and endocrine treatment can trigger hot flashes and headaches (10,11).”
BackgroundSmith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069971 · Cited by 20
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
Shelby, R. A., Dorfman, C. S., Bosworth, H. B., Keefe, F., Sutton, L., Owen, L., Corsino, L., Erkanli, A., Reed, S. D., Arthur, S. S., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.010 · Cited by 18
Labrie, F., & Martel, C. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0042 · Cited by 17
Metadata
- Authors
- Fallowfield, L., Cella, D., Cuzick, J., Francis, S., Locker, G., & Howell, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-11-01
- Volume
- 22
- Issue
- 21
- Pages
- 4261-4271
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101403785
- Cited by
- 310
- References
- 15
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.